Odronextamab
Monoclonal antibody
From Wikipedia, the free encyclopedia
Odronextamab, sold under the brand name Ordspono, is a CD20 x CD3 bispecific monoclonal antibody that is used for the treatment of follicular lymphoma or diffuse large B-cell lymphoma.[1][2] It was developed by Regeneron Pharmaceuticals.[1]
| Monoclonal antibody | |
|---|---|
| Type | Bi-specific T-cell engager |
| Source | Humanized |
| Target | CD20, CD3 |
| Clinical data | |
| Trade names | Ordspono |
| Other names | REGN1979; REGN-1979 |
| Drug class | Antineoplastic |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6458H9950N1728O2020S46 |
| Molar mass | 145593.47 g·mol−1 |
The most common side effects include cytokine release syndrome, infections, neutropenia, pyrexia (fever), anemia, thrombocytopenia, and diarrhea.[1]
Odronextamab was approved for medical use in the European Union in August 2024.[1][2]
Medical uses
Side Effects
The most common side effects include cytokine release syndrome, infections, neutropenia, pyrexia, anemia, thrombocytopenia, and diarrhea.[1]
Society and culture
Legal status
In June 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a conditional marketing authorization for the medicinal product Ordspono, intended for the treatment of follicular lymphoma and diffuse large B-cell lymphoma.[1][3] The applicant for this medicinal product is Regeneron Ireland Designated Activity Company.[1] Odronextamab was approved for medical use in the European Union in August 2024.[1][2][4]
Names
Odronextamab is the international nonproprietary name.[5]
